Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FTO | Q9C0B1 | 10/20 | 0.67 |
| ▸ | MAPT | P10636 | 3/20 | 0.67 |
| ▸ | HPGD | P15428 | 2/20 | 0.67 |
| ▸ | MEN1 | O00255 | 2/20 | 0.67 |
| ▸ | HTT | P42858 | 2/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.67 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.67 |
| ▸ | RECQL | P46063 | 1/20 | 0.67 |
| ▸ | BLM | P54132 | 1/20 | 0.67 |
| ▸ | SMAD3 | P84022 | 1/20 | 0.67 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.67 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.67 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.67 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.52 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29755003 | 1.00 | FTO (0.67) | FTOMAPTHPGDMEN1HTT | |
| SCHEMBL4599673 | 0.91 | FTO (0.66) | FTOMAPTHPGDMEN1HTT | |
| SCHEMBL4282620 | 0.90 | FTO (0.64) | FTOMAPTHPGDMEN1HTT | |
| SCHEMBL22772907 | 0.88 | FTO (0.69) | FTOMAPTHPGDMEN1HTT | |
| SCHEMBL329252 | 0.87 | FTO (0.67) | FTOMAPTHPGDMEN1HTT | |
| SCHEMBL14498109 | 0.87 | FTO (0.67) | FTOMAPTHPGDMEN1HTT | |
| SCHEMBL2334255 | 0.87 | FTO (0.70) | FTOMAPTHPGDMEN1HTT | |
| SCHEMBL30249984 | 0.87 | FTO (0.70) | FTOMAPTHPGDMEN1HTT | |
| SCHEMBL27833470 | 0.86 | FTO (0.83) | FTOMAPTHPGDMEN1HTT | |
| SCHEMBL7599409 | 0.86 | FTO (0.66) | FTOMAPTHPGDMEN1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 613 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12105092-B2 | Molecularly imprinted particles | GEORGE MASON UNIVERSITY (US) | 2024-10-01 | — | — | US | claimed |
| US-20240316171-A1 | COMPOSITIONS AND METHODS FOR TARGETED IMMUNOTHERAPY | DANA FARBER CANCER INST INC (US) | 2024-09-26 | — | — | US | claimed |
| CN-109111913-B | A kind of pair of transmitting cellulose base fluorescent material and its preparation method and application | 中国科学院化学研究所 | 2019-10-01 | — | — | CN | claimed |
| EP-2459229-B1 | USE OF CONSTRAINED DIPEPTIDE AND TRIPEPTIDE MIMIC OLIGOMERS AS VECTORIZATION AGENTS | CENTRE NATIONAL DE LA RECHERCHE SCIENT (C N R S ) (FR) | 2018-02-28 | — | — | EP | claimed |
| US-9061069-B2 | Use of constrained peptide mimic oligomers as vectorization agents | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2015-06-23 | — | — | US | claimed |
| US-8409814-B2 | Sensor proteins and assay methods | Life Technologies Corporation (US) | 2013-04-02 | — | — | US | claimed |
| US-20110111422-A1 | SENSOR PROTEINS AND ASSAY METHODS | Life Technologies Corporation (US) | 2011-05-12 | — | — | US | claimed |
| JP-4651666-B2 | — | — | 2011-03-16 | — | — | JP | claimed |
| US-20090149332-A1 | METHODS FOR DETERMINING THE ACTIVITY OF ADAM-TS PROTEASES USING THIOPEPTOLIDES | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-06-11 | — | — | US | claimed |
| EP-2061884-A2 | SENSOR PROTEINS AND ASSAY METHODS | Invitrogen Corporation (US) | 2009-05-27 | — | — | EP | claimed |
| US-7060441-B2 | Method for fragmenting and labeling DNA involving abasic sites and phosphate labeling | BIOMERIEUX (FR) | 2006-06-13 | — | — | US | claimed |
| WO-2006018572-A2 | METHOD FOR LABELING AND PURIFYING NUCLEIC ACIDS OF INTEREST PRESENT IN A BIOLOGICAL SAMPLE TO BE TREATED IN A SINGLE REACTION VESSEL | BIOMERIEUX (FR) | 2006-02-23 | — | — | WO | claimed |
| EP-1383925-A2 | METHOD FOR LABELLING AND FRAGMENTING DNA | BIO MERIEUX (FR) | 2004-01-28 | — | — | EP | claimed |
| US-20030143555-A1 | Fragmenting the DNA by creating at least one abasic site on DNA, attaching a marker to one of the fragments by means of labeling reagent which is covalently and predominantly coupling to the phosphate of the fragment | BIO MERIEUX (FR) | 2003-07-31 | — | — | US | claimed |
| WO-2002090584-A2 | METHOD FOR LABELLING AND FRAGMENTING DNA | BIO MERIEUX (FR) | 2002-11-14 | — | — | WO | claimed |
| EP-1238116-A1 | PROCESS FOR LABELING A NUCLEIC ACID | BIO MERIEUX (FR) | 2002-09-11 | — | — | EP | claimed |
| US-20020081586-A1 | Process for labeling a nucleic acid | HOLOGIC, INC. | 2002-06-27 | — | — | US | claimed |
| WO-2001044507-A1 | PROCESS FOR LABELING A NUCLEIC ACID | BIO MERIEUX (FR) | 2001-06-21 | — | — | WO | claimed |
| EP-0839068-A1 | ON LINE DETECTION OF A DESIRED SOLUTE IN AN EFFLUENT STREAM USING FLUORESCENCE SPECTROSCOPY | BIOSEPRA INC. (US) | 1998-05-06 | — | — | EP | claimed |
| WO-1996040398-A1 | ON LINE DETECTION OF A DESIRED SOLUTE IN AN EFFLUENT STREAM USING FLUORESCENCE SPECTROSCOPY | BIOSEPRA INC. (US) | 1996-12-19 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030143555-A1 | Fragmenting the DNA by creating at least one abasic site on DNA, attaching a marker to one of the fragments by means of labeling reagent which is covalently and predominantly coupling to the phosphate of the fragment | FEN1, DNMT1, UNG | FTO 1716/4885MAPT 4474/4885HPGD 3910/4885 |
| US-20240316171-A1 | COMPOSITIONS AND METHODS FOR TARGETED IMMUNOTHERAPY | TP53, CD47, MSH2 | FTO 3211/4885MAPT 1095/4885HPGD 3871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.